Compare MEG & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | AURA |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | 3500 | 113 |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 772.3M |
| IPO Year | 2020 | 2021 |
| Metric | MEG | AURA |
|---|---|---|
| Price | $22.14 | $7.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $35.25 | $20.00 |
| AVG Volume (30 Days) | 266.4K | ★ 772.3K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $830,538,000.00 | N/A |
| Revenue This Year | $5.41 | N/A |
| Revenue Next Year | $7.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.26 | N/A |
| 52 Week Low | $19.38 | $4.73 |
| 52 Week High | $32.00 | $9.54 |
| Indicator | MEG | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.09 | 48.84 |
| Support Level | $20.80 | $5.94 |
| Resistance Level | $23.48 | $7.68 |
| Average True Range (ATR) | 0.79 | 0.35 |
| MACD | 0.13 | -0.08 |
| Stochastic Oscillator | 88.92 | 25.90 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits and permits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, and soil remediation. The company derives maximum revenue from United States.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.